52 completed, 5 not yet recruiting, 5 terminated, 2 enrolling by invitation. 23 Phase 1, 15 Phase 2, 12 Phase 3, 5 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 23 | Completed 20, Terminated 3 |
| Phase 2 | 15 | Completed 14, Terminated 1 |
| Phase 3 | 12 | Completed 11, Terminated 1 |
| Phase 4 | 5 | Completed 3, Enrolling by invitation 1, Not yet recruiting 1 |
Follow Emergent BioSolutions: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease. CYFENDUS - Anthrax | Not yet recruiting | Emergent BioSolutions | 250 | 2035-11-01 | 2025-12-08 | |
| A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients AIGIV - Inhalational Anthrax | Not yet recruiting | Emergent BioSolutions | 100 | 2027-05-30 | 2026-02-06 | |
| Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax Collection of samples - Infections, Bacterial | Not yet recruiting | Emergent BioSolutions | 10 | 2027-05-01 | 2026-03-17 | |
| Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario Sample Collection - Infections, Bacterial | Phase 4 | Not yet recruiting | Emergent BioSolutions | 100 | 2027-01-01 | 2026-02-06 |
| Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax AIGIV - Anthrax | Not yet recruiting | Emergent BioSolutions | 10 | 2026-11-30 | 2026-02-06 | |
| Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults Brincidofovir - Smallpox | Phase 1 | Completed | Emergent BioSolutions | 44 | 2023-05-30 | 2025-01-15 |
| Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years CHIKV VLP/adjuvant, Placebo - Chikungunya Virus | Phase 3 | Completed | Bavarian Nordic | 413 | 2022-05-12 | 2024-12-13 |
| Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults 16 mg naloxone AP003, 8 mg naloxone NARCAN Nasal Spray - Opioid Overdose | Phase 1 | Completed | Emergent BioSolutions | 24 | 2022-03-28 | 2026-08-19 |
| Study of SIAN Nasal Spray in Healthy Adults Stabilized Isoamyl Nitrite (SIAN) - Cyanide Poisoning | Phase 1 | Completed | Emergent BioSolutions | 47 | 2021-12-21 | 2025-06-03 |
| A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults COVID-HIG - SARS-CoV-2 Infection | Phase 1 | Completed | Emergent BioSolutions | 23 | 2021-12-07 | 2025-06-08 |
| Universal Influenza A Vaccine in Healthy Adults UFluA 20 µg each antigen/dose, UFluA 60 µg each antigen/dose, Placebo - Human Influenza | Phase 1 | Completed | Emergent BioSolutions | 27 | 2021-12-01 | 2025-01-20 |
| A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine CHIKV VLP, adjuvanted - Chikungunya Virus | Phase 2 | Completed | Bavarian Nordic | 25 | 2021-10-11 | 2023-07-03 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine) CHIKV VLP/adjuvant, Placebo - Chikungunya Virus | Phase 3 | Completed | Bavarian Nordic | 3258 | 2021-09-29 | 2024-08-30 |
| A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults COVID-HIGIV, Placebo (saline) - COVID-19 | Phase 1 | Completed | Emergent BioSolutions | 28 | 2020-12-24 | 2025-06-08 |
| Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) Chikungunya - Chikungunya | Phase 2 | Completed | Bavarian Nordic | 60 | 2019-11-20 | 2024-10-16 |
| Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study Ciprofloxacin 500Mg Tablet, Doxycycline 100Mg Tablet, AV7909 - Anthrax | Phase 2 | Completed | Emergent BioSolutions | 210 | 2019-08-12 | 2025-09-08 |
| VELOCITY: An Anthrax Vaccine Clinical Study AV7909, BioThrax - Anthrax | Phase 3 | Completed | Emergent BioSolutions | 3689 | 2019-03-11 | 2026-05-06 |
| Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG) Zika Virus Immune Globulin (ZIKV-IG), Placebo - Zika Virus Infection, Zika Virus Disease | Phase 1 | Completed | Emergent BioSolutions | 30 | 2018-06-27 | 2024-03-18 |
| Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults CHIKV VLP/unadjuvanted, CHIKV VLP/adjuvanted, Placebo - Chikungunya Virus Infection | Phase 2 | Completed | Bavarian Nordic | 445 | 2018-04-18 | 2023-07-03 |
| Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults VLA1601, Placebo - Zika Virus, Zika Virus Infection | Phase 1 | Completed | Valneva Austria GmbH | 67 | 2018-02-24 | 2019-07-05 |
Showing 20 of 64. Sign in to see all of them.
Anthrax (14) · Smallpox (7) · Cholera (6) · Bacterial Infections (5) · Chikungunya Fever (4) · Vaccinia (4) · Influenza, Human (3) · Inhalation anthrax (3) · Virus Diseases (3) · Arbovirus Infections (2) · Botulism (2) · COVID-19 (2) · Dengue (2) · Flaviviridae Infections (2) · Flavivirus Infections (2)
Biothrax (6) · Anthrax Vaccines (5) · ACAM2000 (4) · Anthrax Immune Globulin Intravenous (3) · raxibacumab (3) · Botulinum Antitoxin (2) · Ciprofloxacin (2) · Smallpox Vaccine (2) · AERAS-402 (1) · AIDSVAX B-E (1) · AVP-21D9 (1) · Cholera Vaccines (1) · Diphenhydramine (1) · Doxycycline (1) · DryVax vaccine (1)
United States (47) · Canada (3) · Australia (2) · Mali (1) · Puerto Rico (1) · Spain (1) · United Kingdom (1)
James McCarty, MD (5) · Bojan Drobic, PhD (2) · Brandon Essink, MD (2) · Gideon Akintunde, MD (2) · Patrick Ajiboye, MD (2) · Robert Hopkins, MD, MPH, TM (2) · Ronald Brown, MD (2) · Abhay Patki, PhD (1) · Alan S Marion, MD, PhD (1) · Bojan Drobic (1) · Chris Cabell, MD, MHS (1) · Christine Hall (1) · Christine Hall, PhD (1)
PMID 35709798, PMID 19587338, PMID 20188175, PMID 23369412, PMID 23701746, PMID 23979731, PMID 24173028, PMID 24733473, PMID 26529238, PMID 27001804, PMID 28566334, PMID 29021299, PMID 29317118, PMID 29624592, PMID 29655627, PMID 30772070, PMID 31209461, PMID 31743334, PMID 31769402, PMID 32333847, PMID 32967791, PMID 34454787, PMID 34610572, PMID 35939501, PMID 36852998, PMID 37376480, PMID 38352727, PMID 39004524, PMID 39954701, PMID 40158524, PMID 40158526, PMID 41401704, PMID 41447782, PMID 42332351